<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39381135</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2516-4236</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Antibody therapeutics</Title><ISOAbbreviation>Antib Ther</ISOAbbreviation></Journal><ArticleTitle>AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains.</ArticleTitle><Pagination><StartPage>307</StartPage><EndPage>323</EndPage><MedlinePgn>307-323</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/abt/tbae025</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">We are entering a new era of antibody discovery and optimization where machine learning (ML) processes will become indispensable for the design and development of therapeutics.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We have constructed a Humanoid Antibody Library for the discovery of therapeutics that is an initial step towards leveraging the utility of artificial intelligence and ML. We describe how we began our validation of the library for antibody discovery by isolating antibodies against a target of pandemic concern, SARS-CoV-2. The two main antibody quality aspects that we focused on were functional and biophysical characterization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The applicability of our platform for effective therapeutic antibody discovery is demonstrated here with the identification of a panel of human monoclonal antibodies that are novel, diverse, and pharmacologically active.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">These first-generation antibodies, without the need for affinity maturation, exhibited neutralization of SARS-CoV-2 viral infectivity across multiple strains and indicated high developability potential.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loomis</LastName><ForeName>Cristina Moldovan</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0009-0003-8089-6950</Identifier><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahlali</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Virology, Evotec ID, 40, Avenue Tony Garnier, 69007 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Citters</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sprague</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neveu</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Virology, Evotec ID, 40, Avenue Tony Garnier, 69007 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somody</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Virology, Evotec ID, 40, Avenue Tony Garnier, 69007 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siska</LastName><ForeName>Christine C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deming</LastName><ForeName>Derrick</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asakawa</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amimeur</LastName><ForeName>Tileli</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaver</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbonelle</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Virology, Evotec ID, 40, Avenue Tony Garnier, 69007 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ketchem</LastName><ForeName>Randal R</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0002-7821-2682</Identifier><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alam</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Virology, Evotec ID, 40, Avenue Tony Garnier, 69007 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Rutilio H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Discovery &amp; Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antib Ther</MedlineTA><NlmUniqueID>101730822</NlmUniqueID><ISSNLinking>2516-4236</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">artificial intelligence</Keyword><Keyword MajorTopicYN="N">developability</Keyword><Keyword MajorTopicYN="N">discovery platform</Keyword><Keyword MajorTopicYN="N">in silico</Keyword><Keyword MajorTopicYN="N">therapeutic antibody</Keyword></KeywordList><CoiStatement>All authors were employees of Just-Evotec Biologics/Evotec at the time all work was performed. All work was performed by employees of Just-Evotec Biologics/Evotec.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39381135</ArticleId><ArticleId IdType="pmc">PMC11456866</ArticleId><ArticleId IdType="doi">10.1093/abt/tbae025</ArticleId><ArticleId IdType="pii">tbae025</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu  R-M, Hwang  Y-C, Liu  I-J. et al.  Development of therapeutic antibodies for the treatment of diseases  J Biomed Sci. 2020;27:1. 10.1186/s12929-019-0592-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0592-z</ArticleId><ArticleId IdType="pmc">PMC6939334</ArticleId><ArticleId IdType="pubmed">31894001</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranayan  H, Dingfelder  F, Butté  A. et al.  Machine learning for biologics: opportunities for protein engineering  Developability and Formulation Trends Pharmacol Sci. 2021;42:151–65. 10.1016/j.tips.2020.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.12.004</ArticleId><ArticleId IdType="pubmed">33500170</ArticleId></ArticleIdList></Reference><Reference><Citation>Amimeur  T, Shaver  JM, Ketchem  RR. et al.  Designing feature-controlled humanoid antibody discovery libraries using generative adversarial networks. BioRxiv  2020. 10.1101/2020.04.12.024844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.12.024844</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulrajani  I, Ahmed  F, Arjovsky  M. et al.  Improved training of Wasserstein GANs. arXIV 2017; arXiv:1704.00028.</Citation></Reference><Reference><Citation>Kerwin  BA, Bennett  C, Brodsky  Y. et al.  Framework mutations of the 10-1074 bnAb increase conformational stability, manufacturability, and stability while preserving full neutralization activity  J Pharm Sci. 2020;109:233–46. 10.1016/j.xphs.2019.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2019.07.009</ArticleId><ArticleId IdType="pmc">PMC6941225</ArticleId><ArticleId IdType="pubmed">31348937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie  A, Shaver  JM. High throughput interrogation of physiochemical properties of a protein. United States patents US11408840B2; US2020003714A1 2020.</Citation></Reference><Reference><Citation>Floyd  JA, Siska  C, Clark  RH. et al.  Adapting the chemical unfolding assay for high-throughput protein screening using experimental and spectroscopic corrections  Anal Biochem. 2018;563:1–8. 10.1016/j.ab.2018.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2018.08.027</ArticleId><ArticleId IdType="pmc">PMC6226613</ArticleId><ArticleId IdType="pubmed">30236889</ArticleId></ArticleIdList></Reference><Reference><Citation>Toprani  V, Joshi  S, Kueltzo  L. et al.  A mico-polyethylene glycol precipitation assay as a relative solubility screening tool for monoclonal antibody design and formulation development  J Pharm Sci. 2016;105:2319–27. 10.1016/j.xphs.2016.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2016.05.021</ArticleId><ArticleId IdType="pubmed">27368120</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu  Y, Caffry  I, Wu  J. et al.  High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy  MAbs. 2014;6:483–92. 10.4161/mabs.27431.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/mabs.27431</ArticleId><ArticleId IdType="pmc">PMC3984336</ArticleId><ArticleId IdType="pubmed">24492294</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli  N, Jain  N, Geddie  ML. et al.  A novel screening method to assess developability of antibody-like molecules  MAbs. 2015;7:752–8. 10.1080/19420862.2015.1048410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2015.1048410</ArticleId><ArticleId IdType="pmc">PMC4622974</ArticleId><ArticleId IdType="pubmed">25961854</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto  D, Park  Y-J, Beltramello  M. et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody  Nature. 2020;583:290–5. 10.1038/s41586-020-2349-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2349-y</ArticleId><ArticleId IdType="pubmed">32422645</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler  ES, Gilchuk  P, Yu  J. et al.  Human neutralizing antibodies against SARS-CoV-2 require intact fc effector functions for optimal therapeutic protection  Cell. 2021;184:1804–1820.e16. 10.1016/j.cell.2021.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.026</ArticleId><ArticleId IdType="pmc">PMC7879018</ArticleId><ArticleId IdType="pubmed">33691139</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost  SJ, Gilchuk  P, Case  JB. et al.  Potently neutralizing and protective human antibodies against SARS-CoV-2  Nature. 2020;584:443–9. 10.1038/s41586-020-2548-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2548-6</ArticleId><ArticleId IdType="pmc">PMC7584396</ArticleId><ArticleId IdType="pubmed">32668443</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruijssers  AJ, George  AS, Schäfer  A. et al.  Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice  Cell Rep. 2020;32:107940. 10.1016/j.celrep.2020.107940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107940</ArticleId><ArticleId IdType="pmc">PMC7340027</ArticleId><ArticleId IdType="pubmed">32668216</ArticleId></ArticleIdList></Reference><Reference><Citation>Almagro  JC, Pedraza-Escalona  M, Arrieta  HI. et al.  Phage display libraries for antibody therapeutic discovery and development  Antibodies (Basel). 2019;8:44. 10.3390/antib8030044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib8030044</ArticleId><ArticleId IdType="pmc">PMC6784186</ArticleId><ArticleId IdType="pubmed">31544850</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim  H. Synthetic approach to the generation of antibody diversity  BMB Rep. 2015;48:489–94. 10.5483/BMBRep.2015.48.9.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2015.48.9.120</ArticleId><ArticleId IdType="pmc">PMC4641231</ArticleId><ArticleId IdType="pubmed">26129672</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria-Rose  NA, Joyce  MG. Strategies to guide the antibody affinity maturation process  Curr Opin Virol. 2015;11:137–47. 10.1016/j.coviro.2015.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2015.04.002</ArticleId><ArticleId IdType="pmc">PMC4456294</ArticleId><ArticleId IdType="pubmed">25913818</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel  A, Gupta  V, Hickey  J. et al.  Coformulation of broadly neutralizing antibodies 3BNC117 and PGT121: analytical challenges during preformulation characterization and storage stability studies  J Pharm Sci. 2018;107:3032–46. 10.1016/j.xphs.2018.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2018.08.012</ArticleId><ArticleId IdType="pmc">PMC6269598</ArticleId><ArticleId IdType="pubmed">30176252</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailly  M, Mieczkowski  C, Juan  V. et al.  Predicting antibody Developability profiles through early stage discovery screening  MAbs. 2020;12:1743053. 10.1080/19420862.2020.1743053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2020.1743053</ArticleId><ArticleId IdType="pmc">PMC7153844</ArticleId><ArticleId IdType="pubmed">32249670</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark  RH, Latypov  RF, De Imus  C. et al.  Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs  MAbs. 2014;6:1540–50. 10.4161/mabs.36252.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/mabs.36252</ArticleId><ArticleId IdType="pmc">PMC4622659</ArticleId><ArticleId IdType="pubmed">25484048</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>